Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 1, 2010, Pages 30-39

  Schnell Inderst, Petra ^a   Schwarzer, Ruth ^a   Göhler, Alexander ^a   Grandi, Norma ^a   Grabein, Kristin ^b   Stollenwerk, Bjrn ^c   Manne, Jennifer ^a   Klauss, Volker ^d   Siebert, Uwe ^a   Wasem, Jürgen ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Coronary artery disease; Cost effectiveness; Health technology assessment; High sensitivity C reactive protein; Risk prediction; Systematic review

Indexed keywords

C-REACTIVE PROTEINS; CORONARY ARTERY DISEASE; HEALTH TECHNOLOGY ASSESSMENTS; HIGH-SENSITIVITY; RISK PREDICTIONS; SYSTEMATIC REVIEW;

COST EFFECTIVENESS; COSTS; DECISION MAKING; DECISION THEORY; DISEASES; HEALTH; HEART; MATHEMATICAL MODELS; PROTEINS; TECHNOLOGICAL FORECASTING;

HEALTH RISKS;

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIFE EXPECTANCY; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; AGE; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

AGE FACTORS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 77949885183     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990870     Document Type: Article

References (44)

1. Allender S, Scarborough P, Peto V, et al. European cardiovascular disease statistics 2008. 2008 edition. In: Network EH, ed. Oxford, UK: British Heart Foundation Health Promotion Research Group. Department of Public Health, University of Oxford and Health Economics Research Centre, Department of Public Health, University of Oxford, 2008;1-113. http://www.ehnheart.org/files/ statistics%202008%20web- 161229A.pdf (accessed September 29, 2008).
2. Altman D. Systematic reviews of evaluations of prognostic variables. In: Egger M, Smith GD, Altman DG, editor. London: BMJ Publishing Group; 2001.
3. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated Creactive protein levels. J Am Coll Cardiol. 2002;40:49-55.
4. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. American Journal of Medicine. 2003;114:485-494
5. Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim2929). Stat Med. 2008;27:191-195.
6. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
7. Cook NR, Buring JE, Ridker PM. The effect of including Creactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-29
8. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
9. Danesh J,Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397
10. Danesh J,Whincup P,Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updatedmetaanalyses. BMJ. 2000;321:199-204.
11. Ess SM, Szucs TD. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ital Heart J. 2001;2:181-188
12. Ess SM, Szucs TD. Economical aspects of high-sensitivity Creactive protein as predictor of coronary heart disease: An analysis in France, Spain and Switzerland. HeartDrug. 2002;2:61-68
13. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368-1373
14. German ScientificWorking Group Technology Assessment for Health Care. "Toolkit" Informationsmaterial für Verfasser von HTA-Berichten. Hannover. Stand 2000. 2000
15. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):E1-E40. (Pubitemid 47342420)
16. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863-1867.
17. Harrell FE. Regression modeling strategies. 1st ed. New York: Springer; 2001.
18. Hlatky MA. Expanding the orbit of primary prevention - Moving beyond JUPITER. N Engl J Med. 2008;359:2280-2282.
19. Kaul A. C-reactive protein for diagnosis and screening of coronary artery disease (Structured abstract). Health Technology Advisory Committee (HTAC). 2002. http://www. crd.york.ac.uk/CRDWeb/ShowRecord.asp?View=Full&ID= 32003000446.
20. Klee G, Jaffa A, Lakatua D. Biochemical markers of cardiovascular disease risk (Structured abstract). Institute for Clinical Systems Improvement (ICSI). 2003. http://www.icsi. org/guidelines-and-more/technology-assessment-reports/ tech nology-assessment-reports-active/biochemical-markers-of-cardiovascular- disease-risk.html.
21. Koenig W, Lowel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349-1353
22. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med. 2004;116:9-16.
23. Lloyd-JonesDM, LiuK, Tian L, et al. Narrative review:Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
24. McGeechan K, Macaskill P, Irwig L, et al. Assessing new biomarkers and predictive Models for use in clinical practice. A clinician's guide. Arch Intern Med. 2008;168:2304-2310.
25. Myers GL, Rifai N, Tracy RP, et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Report from the Laboratory Science Discussion Group. Circulation. 2004;110:e545-e549.
26. OECD Health Data: Gross product purchasing power parities 2007 http://www.oecd.org/linklist/0,2678,en-2649-34357-2734617-1-1-1- 1,00.html (30.4.2007).
27. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J. 2007;28:1374-1381.
28. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for DiseaseControl and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172; discussion 207-212.
30. Randolph AG, Guyatt GH, Calvin JE, Doig G, RichardsonWS, Scott W. Understanding articles describing clinical prediction tools. Crit Care Med. 1998;26: 1603-1612
31. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138.
32. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195-2207.
33. Ridker PM, Rifai N, Clearfield M, et al. Measurement of Creactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
34. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844.
35. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565
36. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217-223.
37. Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econom. 2003;4:143-150.
38. Siebert U, Behrend C, Mühlberger N, Wasem J, Greiner W, v.d.Schulenburg J-M, Welte R, Leidl R, editors. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. Baden- Baden: Nomos; 1999.
39. Statistisches Bundesamt Deutschland: Allgemeiner Verbraucherpreisindex 2007 http://www.destatis.de/indicators/ d/vpi101ad.htm (30.4.2007).
40. St-PierreAC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of theQuebecCardiovascular Study. Atherosclerosis. 2005;182:315-321
41. Van Der Meer IM, deMaat MP,Kiliaan AJ, et al. The value of Creactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003 163:1323-1328
42. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M. Cost-effectiveness of using prognostic information to select womenwith breast cancer for adjuvant systemic therapy. Health Technology Assessment 2006;10.
43. Wilson PW, Nam BH, Pencina M, et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005 Nov 28;165(21):2473-2478
44. Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1:92-97.